{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:10:04Z","timestamp":1756314604096,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,4,2]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>A 62-year-old man presented to our institute with diarrhoea and dysuria on a background of subtotal colectomy and end ileostomy and biological therapy for Crohn\u2019s disease. He was diagnosed with urinary tract infection and acute kidney injury (AKI). Renal ultrasound suggested left hydronephrosis, with renal protocol computed tomography (CT) showing a large pelvic mass. Magnetic resonance imaging (MRI) of the pelvis demonstrated a rectal tumour invading the bladder and compressing both ureters. He underwent cystoscopy, flexible sigmoidoscopy and positron emission tomography\u2013CT and was diagnosed with stage IV non-Hodgkin\u2019s diffuse large B-cell lymphoma. He was treated primarily with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin and prednisolone chemotherapy regimen. He had ongoing urosepsis before admission for pelvic exenteration. He underwent cystoprostatectomy, excision of rectal stump and formation of ileal conduit. Histology showed no signs of residual malignancy. One year later, the patient was admitted to the intensive care unit with aspiration pneumonia, urosepsis and AKI. Despite maximal therapy, he developed multiorgan failure and passed away.<\/jats:p>","DOI":"10.1136\/bcr-2018-228818","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:05:12Z","timestamp":1587107112000},"page":"e228818","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Diffuse large B-cell lymphoma of the rectum in a patient with Crohn\u2019s disease"],"prefix":"10.1136","volume":"13","author":[{"given":"Adam Joseph","family":"Hardy","sequence":"first","affiliation":[{"name":"Department of Paediatric Surgery, Our Lady's Children's Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ionica","family":"Stoica","sequence":"additional","affiliation":[{"name":"Department of General & Vascular Surgery, Tallaght Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Edward","family":"Kearney","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Limerick, Limerick, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diarmuid S","family":"O'Riordain","sequence":"additional","affiliation":[{"name":"Department of Surgery, Tallaght University Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2025082709365314000_13.4.e228818.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.02.004"},{"key":"2025082709365314000_13.4.e228818.2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i29.9675"},{"key":"2025082709365314000_13.4.e228818.3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4291\/wjgp.v6.i4.181","article-title":"Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders","volume":"6","author":"Lam","year":"2015","journal-title":"World J Gastrointest Pathophysiol"},{"key":"2025082709365314000_13.4.e228818.4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-015-1877-0","article-title":"Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis","volume":"71","author":"Wang","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2025082709365314000_13.4.e228818.5","unstructured":"National Institute for Health and Care Excellence . Infliximab and adalimumab for the treatment of Crohn\u2019s disease, 2010. Available: https:\/\/www.nice.org.uk\/guidance\/TA187\/chapter\/1-Guidance [Accessed 29 Oct 2018]."},{"key":"2025082709365314000_13.4.e228818.6","unstructured":"Penner RM , Fedorak RN . Adalimumab for treatment of Crohn\u2019s disease in adults. In: Post TW , ed. UpToDate. Waltham, MA: UpToDate, 2015."},{"key":"2025082709365314000_13.4.e228818.7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/ibd.21516","article-title":"Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era","volume":"17","author":"Holubar","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2025082709365314000_13.4.e228818.8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.surge.2014.01.002","article-title":"Primary colorectal lymphoma - A single centre experience","volume":"13","author":"Tevlin","year":"2015","journal-title":"Surgeon"},{"key":"2025082709365314000_13.4.e228818.9","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu010"},{"key":"2025082709365314000_13.4.e228818.10","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.30328"},{"key":"2025082709365314000_13.4.e228818.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.001"},{"key":"2025082709365314000_13.4.e228818.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61302-7"},{"key":"2025082709365314000_13.4.e228818.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.05.015"},{"key":"2025082709365314000_13.4.e228818.14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12624"},{"key":"2025082709365314000_13.4.e228818.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10067-015-3115-7","article-title":"Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses","volume":"35","author":"Chen","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025082709365314000_13.4.e228818.16","first-page":"67","article-title":"How to improve the safety of biologic therapy in Crohn's disease","volume":"60","author":"Ferkolj","year":"2009","journal-title":"J Physiol Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-228818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:37:00Z","timestamp":1756312620000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-228818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bcr-2018-228818"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-228818","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}